Integrated Summary Report
Who We Are: Our Culture
At Lilly, we create new medicines that give people new hope – to get better, feel better, live better.
It’s not just what we do. It’s who we are.
Throughout our history, Lilly researchers have been driven by the desire to make a meaningful difference for people living with diseases that rob them of hope and good health.
That’s why we’re urgently pushing the boundaries of science, advancing new discoveries with the latest technology so that diseases causing major harm today will see meaningful healing tomorrow.
Far too many diseases cannot be cured or managed. Though much work remains, and while there will be setbacks, new pathways and technologies offer hope of finding treatments that can slow or even stop them.
When we're at our best, we unite caring with discovery to create medicines that make life better - for you, your loved ones, and the people in your community. Being at our best helps you be at yours.
David A. RicksChairman and CEO, Eli Lilly and Company
How We Operate
Our work is driven by the needs of patients and guided by our enduring values – integrity, excellence and respect for people.
Lilly has a long heritage of strengthening the communities where we work and live. We use our resources responsibly while also sharing with those in need to improve the health of communities around the world. Through our global health and corporate responsibility efforts, we continually look for new ways to extend the promise of better health to more people.
Striving to make patients’ costs affordable is critical to help them stay on their medicines and stay healthy. We’re committed to working with others in the health care system to make sure patients can get the medicines they need – at reasonable out-of-pocket costs and with pricing information they can understand.
To help people, we believe it’s vital to include people. To support our strategy of innovation, we must have a culture of inclusion – so everyone can bring diverse ideas, perspectives and experiences in the pursuit of our purpose.
Lilly's Growth: Our Results
We're in an exciting new growth era at Lilly.
2018 was a momentous year for Lilly, with strong financial growth. We also concluded our strategic review of our Elanco Animal Health subsidiary, deciding to separate Elanco with an initial public offering in 2018 and complete divestiture in 2019. Lilly will now be focused on discovering and delivering new human medicines that change expectations for patients and drive results for shareholders.
